ERBB2 somatic mutation
Tuesday 8 October 2013
ERBB2 somatic mutations
ERBB2/HER2, best known for its role in breast cancer tumorigenesis, can be targeted by two types of pharmacological manipulation: antibody therapy against the extracellular receptor domain and small molecule compounds against the intracellular tyrosine kinase domain.
Aberrant activation of ERBB2 by gene amplification has been shown to participate in the pathophysiology of breast, ovarian, gastric, colorectal, lung, brain, and head and neck tumors.
The advent of next-generation sequencing technologies has enabled efficient identification of activating molecular alterations of ERBB2.
ERBB2 somatic mutations in
- pulmonary adenocarcinoma (MIM.211980)
- glioblastoma (MIM.137800)
- gastric adenocarcinoma (MIM.137215)
- ovarian carcinomas
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.
Herter-Sprie GS, Greulich H, Wong KK. Front Oncol. 2013;3:86. doi:10.3389/fonc.2013.00086 . PMID: #23630663#
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O.
J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi:10.1200/JCO.2012.45.609. PMID: #23610105#